Drugs, Pregnancy & Lactation

Q&A with the FDA: Implementing the Pregnancy and Lactation Labeling Rule


 

Q: Does the FDA have any plans to address labeling for over-the-counter products in terms of their impact on pregnancy, lactation, and reproductive potential?

A: The PLLR does not apply to over-the-counter products. However, the agency is continually reviewing the safety of products used over the counter, including impacts on pregnancy, lactation, and reproductive potential.

Q: How does the FDA plan to assess over time the usefulness of the new labeling for prescribers and patients and make revisions?

A: The draft guidance was issued concurrently with PLLR. Based on the comments received from the public on the draft, as well as learning from the initial revisions of labeling, the guidance will be revised as needed. Guidance statements issued by FDA are regularly reviewed and revised as needed.

Dr. Whyte, a board-certified internist, is the director of Professional Affairs and Stakeholder Engagement at the FDA. Do you have other questions about the PLLR? Send them to obnews@frontlinemedcom.com.

Pages

Recommended Reading

Electronic fetal monitoring fails to predict brain injury
MDedge Neurology
Maternal age, cardioseptal defects are major risk factors for peripartum thrombosis
MDedge Neurology
Prenatal drug exposure alters brain’s organization
MDedge Neurology
VIDEO: Don’t forget folate for women on antiepilepsy drugs
MDedge Neurology
ACOG: IV regimen safely resolved acute headache in pregnant women
MDedge Neurology
NASPAG: Migraines don’t always preclude combined OCs
MDedge Neurology
PAS: Supplemental iron during and after pregnancy affects infant behavior
MDedge Neurology
Delayed cord clamping linked to better neurodevelopmental outcomes
MDedge Neurology
Expert: Don’t discourage pregnancy in MS patients; manage it
MDedge Neurology
Worsening migraine in pregnancy linked to adverse outcomes
MDedge Neurology

Related Articles